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Background and purpose: We investigated clinical outcomes of proton beam concurrent chemoradiother-
apy (CCRT) for unresectable, locally advanced pancreatic cancer (LAPC) patients.
Materials and methods: Records from 42 unresectable LAPC patients (21 male and 21 female, 39–83 years
old) with IIB/III clinical staging of 1/41 treated by proton beam CCRT were retrospectively reviewed.
Twelve patients received a conventional 50 Gray equivalents (GyE) in 25 fractions protocol and 30 others
received a higher dose protocol of 54.0–67.5 GyE in 25–33 fractions. Gemcitabine or S-1 (Tegafur,
Gimeracil and Oteracil) was used concurrently. Toxicity, overall survival (OS) and local control (LC) were
examined.
Results: Acute adverse events of grades 1, 2, 3 and 4 were found in 4, 15, 17 and 2 patients, respectively.
All grade 3 and 4 events were hematologic. Late adverse events of grades 1 and 2 were found in 3 and 2
patients, respectively. No late adverse effects of grade 3 or higher were observed. The 1-year/2-year OS
rates from the start of CCRT were 77.8/50.8% with median survival time (MST) of 25.6 months. The 1-
year/2-year LC rate from CCRT start was 83.3/78.9% with a median time to local recurrence of more than
36 months. Total irradiation dose was the only significant factor in univariate analyses of OS and LC
(p = 0.015 and 0.023, respectively).
Conclusion: Proton beam CCRT lengthened survival periods compared to previous photon CCRT data and
higher dose irradiation prolonged LC and OS for unresectable LAPC patients. Proton beam therapy is
therefore safe and effective in these cases.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 136 (2019) 37–43 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Pancreatic cancer carries a very poor prognosis and the number
of deaths per year it causes has steadily risen to approximately
35,000 in 2013, making it the fourth leading cause of cancer deaths
in Japan [1]. Surgical resection is currently the only curative treat-
ment but less than 20% of cases are resectable at presentation and
up to 25–30% of newly diagnosed patients with non-distant meta-
static lesions are divided into borderline resectable and unre-
sectable locally advanced pancreatic cancer (LAPC) patients based
upon the extent of vascular involvement [2].
In recent years, intensive chemotherapies such as FOLFIRINOX
and a combination of gemcitabine (Gem) and nab-Paclitaxel have
improved clinical outcomes of unresectable LAPC patients [3,4];
however, many patients have difficulty in continuous treatment
due to serious incidences of adverse events [5,6]. Concurrent
chemoradiotherapy (CCRT) is another treatment option for unre-sectable LAPC patients. In the CCRT of unresectable LAPC, Gem is
one of the most often used and recommended anticancer drugs
in Japan [7]. With a broad spectrum of antitumor activity against
a variety of solid tumors, it also acts as a potent radio-sensitizer
in pancreatic cancers [8]. Clinical trials of concurrent Gem and
radiotherapy have shown a greater effect than 5-fluorouracil
(5-FU) CCRT for LAPC patients [9–11]. Outside of Gem, the
combination of Tegafur/Gimeracil/Oteracil (S-1) has been proven
comparable to Gem in the CCRT of LAPC patients [12,13].
The ultimate goal of radiotherapy within the context of CCRT for
the unresectable LAPC patients is local control of the tumor and
conventional photon RT delivered from 3 or 4 directions is most
often chosen for this purpose. Pancreatic tumors are difficult to
approach due to their close proximity to the gastrointestinal tract
(GI tract), whose radiation sensitivity precludes sufficient delivery
of on-target energy [14]. Therefore, a total irradiation dose of 50
gray (Gy) (daily 1.8–2 Gy) is recommended for the treatment of
LAPC patients in Japan. Unfortunately, the 50 Gy dose of radiother-
apy is only palliative against aggressive pancreatic cancers. Proton
beams, on the other hand, can provide less penetration, prevent
38 PBT for unresectable LAPCerrant energy delivery to non-tumor targets, and deliver higher
doses to the tumor than photon RT.
The purpose of this study is to therefore investigate the clinical
outcomes of CCRT using proton beams for unresectable LAPC
patients.Methods and materials
Patients
A total of 42 unresectable LAPC patients treated with CCRT
using proton beams at our institute between July 2009 and March
2016 were retrospectively reviewed. This study included 21 men
and 21 women, whose age ranged from 39 to 83 (median: 66)
years. Computed tomography (CT) or magnetic resonance imaging
(MRI) with contrast agents was performed for staging prior to PBT
in all patients. Re-evaluation in our institute was performed for 32
patients who had already received chemotherapy at their initial
hospital. Clinical staging of IIB/III was 1/41 according to the Union
for International Cancer Control (UICC) TNM staging system (7th
edition). Regional lymph nodes were defined in accordance with
the UICC system as superior and inferior to the head and body of
the pancreas, anterior pancreaticoduodenal, posterior pancreatico-
duodenal, common bile duct, and proximal mesenteric lymph
nodes. Pyloric and celiac lymph nodes were included for head of
pancreatic tumors, and the hilum of the spleen and the tail of the
pancreatic lymph nodes were included for body and tail of it.
‘‘Unresectable” was defined as tumors involving more than 180
degree of celiac artery (CA) or superior mesenteric artery (SMA)
on CT scan. A total of 32 patients had already received chemother-
apy at their initial hospital before they came to our institute
(Table 1). Pre-treatment chemotherapy outside of our center in
32 patients was done at their previous physician’s discretion and
included GEM, S-1, FOLFOX, nab-PTX and combinations.
All procedures involving human participants, including case
reviews of treatments, were conducted in accordance with the eth-
ical standards of the 1964 Helsinki declaration and its later amend-
ments (or comparable ethical standards) and approved by the
University of Tsukuba Institutional Research Committee (Approval
# H29-080). All treatments were discussed at an in-hospital con-
ference and informed consent was obtained from all participants
included in the study. We got informed consent from either living
patients or the legally designated next-of-kin for those who died,
as appropriate.Proton beam therapy
Before making a treatment plan, CT images without intravenous
contrast agent were taken at 2.5 mm intervals during the expira-Table 1
Patients’ characteristics.
Number of patients 42
Age 39–83 (66)
Sex (M/F) 21/21
T (3/4) 1/41
N (0/1) 27/15
Stage (IIB/III) 1/41
Total irradiation dose (50 GyE/>50 GyE) 12/30
Pre-treatment (chemotherapy) 32
Concurrent
Chemotherapy (GEM/S-1) 38/4
Chemotherapy + hyperthermia 23
Post treatment (chemotherapy/surgery) 34/2
The number inside the brackets means median value.
Abbreviations: GEM: Gemcitabine, S-1: Tegafur/Gimeracil/Oteracil, GyE: gray
equivalent.tory phase under a respiratory gating system [15]. We defined
the gross tumor volume as primary tumor and metastatic regional
lymph nodes. The clinical target volume (CTV) was judged to be an
approximately 5 mm margin around the gross tumor volume and
the roots of celiac or superior mesenteric arteries (CA, SMA) were
involved in cases of lesions which had invaded around the vessels.
Regional but non-metastatic regional lymph nodes were not
included in the CTV. The stomach, duodenum and intestine were
counted as GI tract for our purposes. Beam-dependent margins
were directly added to the CTV, such as a 1 cm margin around
the CTV, and a 5-mm margin was added to the caudal direction
to compensate for unexpected respiration-induced movements.
Total irradiation doses were 50 Gray equivalents (GyE) with 25
fractions in 12 cases, 54 GyE in 27 fractions in 2 cases, 56 GyE in
28 fractions in 4 cases, 59.4 GyE in 33 fractions in 1 case, 60 GyE
in 30 fractions in 6 cases, and 67.5 GyE in 25 fractions (concomi-
tant boost technique) in 17 cases. The protocol was decided by irra-
diation dosage sustained by the GI tract, which is mainly derived
from tumor location. In the concomitant boost technique, 50 GyE
was delivered to cover the entire CTV by anterior and posterior
beams and another posterior beam of 17.5 GyE was added as in
Terashima’s method [16] (Supplementary Fig. 1). The essence of
this method is that the boost beam be processed so as not to reach
the GI tract. This method was slightly modified so that the irradi-
ation dose of the GI tract in the boost beam was less than 10% of
the isocenter dose. We set the dose constraints for the GI tract at
50 GyE and in only 1 patient was the duodenal dose beyond
50 GyE due to the tumor’s location. However, we accepted this
plan since the volume and dose was small (D0.1cc: 51.8 GyE). The
relative biological effectiveness value was determined to be 1.1
[17]. During treatment, all patients were treated with 155–
230 MeV proton beams, using a passive spreading method, and
beams were delivered at the expiratory phase for a maximum of
0.3 seconds under free-breathing conditions [18]. Spinal bones
and 2 sets of orthogonal digital radiographs were used for daily
confirmation of the position. We routinely use proton-pump inhi-
bitors to preserve the GI tract during the treatment course and
treatment was performed after at least 3 hours of fasting (6 hours
if the pancreas was especially close to the GI tract).Concurrent and adjuvant therapy
All patients received concurrent chemotherapy (Gem: 38, S-1:
4). Briefly, Gem dosage was 250 mg/m2 (maximum 6 times) for
outpatients and 800 mg/m2 (maximum 3 times) for inpatients
until 2013 after which it was prescribed under a unified 800 mg/
m2 protocol for all patients. In this study, 15 patients were treated
with 250 mg/m2 and 23 with 800 mg/m2 protocols. Gem was
administered during the treatment course and was skipped when
the absolute granulocyte count was less than 2000/mm3, the plate-
let count was less than 70000/mm3 on a scheduled dosage day, or
if any condition diagnosed by physicians contraindicated adminis-
tration. The oral dosage of S-1 was prescribed twice daily, 5 times a
week according to body-surface area (<1.25 m2, 80 mg/day; >1.25
to <1.5 m2, 100 mg/day; >1.5 m2, 120 mg/day) and was also
skipped whenever contraindicated by performance status, blood
and/or biochemical data.
A total of 23 patients received hyperthermia during the treat-
ment course depending on machine availability. Hyperthermia
was administered at 60 min/session once a week immediately after
proton beam therapy (PBT), 5 to 6 times in total, employing an 8-
MHz RF-capacitive heating device (Thermotron-RF8; Yamamoto
Vinita Co., Ltd., Osaka, Japan).
A total of 36 patients received adjuvant therapy after PBT
(chemotherapy 34, surgery 2). Adjuvant therapy was contraindi-
cated in the remaining 6 patients due to their physical condition.
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All patients were scheduled to come to our institute every
3 months and imaging examinations were conducted prior to their
visit if their physical condition was well. Acute and late toxicities
were evaluated according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE, version 4.0) [19].
Relapse was evaluated according to the Response Evaluation Crite-
ria in Solid Tumors (version 1.1) [20]. Univariate analyses for prog-
noses were examined using Cox’s regression. For the analysis of
characteristics such as age, tumor diameters and CA19-9, we made
two well-balanced groups from patients. In the analysis of total
irradiation doses, they were classified into conventional (50 GyE)
and higher (>50 GyE) groups because a well-balanced and delim-
ited value was not found. We examined overall survival (OS) and
local control (LC) rates using the Kaplan–Meier method and com-
parisons were done by log rank test. Correlation between LC and
OS were examined using Pearson’s correlation coefficient. All anal-
yses were performed using SPSS version 24.0 (IBM Inc. Armonk,
NY, USA). A p value <0.05 was defined as significant.Results
As of July 2018, a total of 21 patients were alive, and 21 remain-
ing patients had died of pancreatic cancer. The follow-up period
range was 2.4–47.6 (median: 14.0) months in all patients and
3.4–47.6 (median: 14) months in the living patients. A total of 25
patients showed recurrence after treatment (local recurrence: 6,
distant metastases: 17, and both: 2).
Acute adverse events of grades 1, 2, 3 and 4 were found in 4, 15,
17 and 2 patients, respectively. All grade 3 and 4 events were
hematologic. Late adverse events of grades 1 and 2 were found in
3 and 2 patients, respectively (gastric ulcer at 5.3 months and
anorexia in at 12.5 months after PBT). Acute adverse events more
than grade 5 and late adverse events more than grade 3 were not
observed. Details of the acute and late toxicities are shown in
Table 2.
The OS rate at 1-year/2-year from the start of CCRT was
77.8/50.8% with median survival time (MST) of 25.6 months and
OS from the initial treatment was 84.5/58.7% with an MST of
27.5 months. The 1-year/2-year LC rate from the start of CCRT
was 83.3/78.9% with a median time to local recurrence of more
than 36 months and LC from the initial treatment was 90.1/76.7%
with a median time to local recurrence of more than 36 monthsTable 2
Outcome of the patients and adverse events.
Number of patients OS from
CCRT
1 Y/2 Y
(median)
OS from
initial Tx
1 Y/2 Y
(median)
LC from
CCRT
1 Y/2 Y
(median)
LC from
initial Tx
1 Y/2 Y
(median)
42 77.8/50.8%
(25.6 M)
84.5/58.7%
(27.5 M)
83.3/78.9%
(>36 M)
90.1/76.7%
(>36 M)
Adverse events Acute
CTCAE ver 4.0 Grade 1 2 3
Hematologic Leukopenia 5 15 1
Neutropenia 7 14 1
Anemia 26 8 2
Thrombocytopenia 24 6 2
Gastrointestinal Nausea 2
Vomiting
Anorexia 2
Gastric ulcer
Abbreviations: OS: overall survival, LC: local control, Tx: treatment, Y: years, M: months
Grade of upper table shows the maximum grade of each patient.
Grade of lower table shows every events.(Table 2, Fig. 1). Local recurrence was observed in 8 patients, with
six suffering from local recurrence within 1 year and 5 dying
within 18 months. On the other hand, 22 out of 24 patients who
did not have local recurrence within 1 year did not suffer from
local recurrence until death or final follow-up (Supplementary
Fig. 2). The MST of the patients without local recurrence was
25.6 months, much longer than that of those with local recurrence
(13.1 months).
With regard to prognostic factors, only the total irradiation dose
was significant in OS and LC in univariate analyses and patients
receiving higher doses showed longer OS and LC (p = 0.015 and
0.023, respectively), (Table 3, Fig. 2-(a, b)). A more detailed analysis
of classifying patients into three groups by the irradiation dosage is
shown in Fig. 2-(c, d). The median OS was 13.1, 28.4, and
42.5 months for 50, 54–60, and 67.5 GyE protocols, respectively,
and median time to local recurrence was 10.9 months in 50 GyE
and more than 36 months in the 54–60 and 67.5 GyE protocols,
respectively. Higher doses caused a superior trend in OS and LC.
Fig. 3 depicts a representative case of a 71-year old man with
unresectable LAPC. The primary tumor was located in the pancre-
atic body and clinical staging was T4N0M0. He received proton
beam therapy to a total dose of 67.5 GyE in 25 fractions (using
the concomitant boost technique) concurrently with chemother-
apy (Gem: 800 mg/m2; 3 times) and hyperthermia (6 times) during
the treatment course. Reduced tumor volume was observed
25 months later. This patient is still alive without local recurrence
or distant metastases 37 months after CCRT using proton beams.Discussion
Clinical studies of CCRT reported in LAPC patients are summa-
rized in Supplementary Table 1. For 3-dimensional conformal
radiotherapy (3DCRT), the OS ranges from 2.8 to 13% at 2 years
and the MST ranges from 10.3 to 15.8 months [21–25]. As for
intensity modulated radiotherapy (IMRT), the OS range is 22–
32.9% at 2 years and MST ranges from 15.3 to 22.6 months with
two recently published reports of IMRT indicating MSTs of over
20 months [25–28]. In an IMRT study that delivered a 60–66 Gy
dose to a macroscopic tumor using a simultaneous and integrated
boost technique, the MST was 19 months and the median time to
local recurrence was 13 months [29]. Stereotactic body radiother-
apy succeeded in shortening the treatment period and the MST
ranged from 10.6 to 15 months [30–32]. A large cohort study withSite of recurrence
local/distant/both
Death of disease Adverse events
(grade 1/2/3/4/5)
Acute Late
7/17/2
(16.7/40.5/4.8%)
21
(50%)
4/15/17/2/0 3/2/0/0/0
Late
4 5 1 2 3 4 5
7
3 2
1
1 1
3 1
.
Fig. 1. Survival curves. (a) Overall survival rate. (b) Local control rate.
Table 3
Analysis of prognostic factors.
OS LC
Univariate
analysis
Univariate
analysis
Age (565 vs > 65) 0.144 0.516
Sex 0.792 0.802
N (0 vs 1) 0.397 0.742
Tumor diameter (530 mm vs > 30 mm) 0.195 0.805
CA19-9 (5200 U/mL vs > 200 U/mL) 0.203 0.509
Pre-treatment (with vs without) 0.357 0.281
Total irradiation dose (50 GyE
vs > 50 GyE)
0.015* 0.023*
Hyperthermia (presence vs absence) 0.355 0.252
* Significant.
40 PBT for unresectable LAPCpropensity matching reported that the outcome of SBRT was not
inferior to IMRT and was at least improved over conventional radi-
ation techniques [33]. As for proton beam therapy (PBT), some
dosimetry studies have confirmed a physical advantage of proton
beams over photon beams, namely a tissue-sparing benefit, leading
to the idea that outcomes may be improved by safely increasing
proton beam doses [34,35]. In the clinical PBT studies, the OS
ranges from 31 to 45% at 2 years with an MST between 18.4 and
22.3 months although the reports are very few and the patient
cohort was smaller than in photon beam studies [16,36,37]. Our
data, in which the 2-year OS is 50.8% with MST of 25.6 months,
is numerically superior to photon RT and equivalent or superior
to PBT even when borderline resectable patients are omitted and
only unresectable LAPC patients are analyzed. Moreover, the 1-
year/2-year OS and LC were 67.1%/11% and 49.2%/0%, respectively,
while MST and median time to local recurrence were 15.7 and
10.6 months, respectively, for 25 patients who received conven-
tional photon chemoradiotherapy (50–50.4 Gy) at our institute at
the same time as this study. These data suggest that PBT has a
potential of superior anti-tumor effect over existing RT for the
treatment of unresectable LAPC patients [21–33].
Reasoning for the superiority of PBT is based on higher dose
delivery, as patients with higher doses had a significantly longerOS compared to conventional dosing. However, it is premature to
state that higher doses universally lead to better outcomes as the
challenging 67.5 GyE protocol still risks high dose exposure to
the GI tract. Therefore, although the classification numbers may
shrink, there needs to be a more detailed examination of the rela-
tionship between irradiation dose and outcome. To this end, our
study used 50 GyE, 54 to 60 GyE and 67.5GyE classifications and,
as a result, we found that higher doses did trend toward longer
LC and OS.
During the study period, a total of 19 patients experienced
Grade 3 or 4 acute adverse events. However, these events were
hematologic and can be explained by chemotherapy. As for gas-
trointestinal events, no patient suffered from more than a grade
2 event, lending credence the lower acute toxicity of PBT. Further-
more, no patient manifested a late GI-related adverse event of
more than Grade 3, reinforcing the idea of CCRT using proton
beams as a relatively less adverse modality compared to more
aggressive therapies. In the previous study of Nichols et al. [38],
it was verified that PBT in the range of 50.4–59.4 GyE was safely
performed without any grade 3 GI toxicity. However, with regard
to the 67.5 GyE in 25 fractions protocol, Takatori, et al. [39]
reported PBT-induced ulcers in 45/91 patients from the same insti-
tute as the Terashima, et al. study [16]. Although we cannot
directly compare treatment planning and methods in detail, the
main difference between the Terashima, et al. study and ours is
in the definition of the CTV. They included the primary tumor plus
metastatic regional lymph nodes with prophylactic regions con-
taining the drainage lymph nodes and paraaortic lymph nodes.
Their CTV also involved peripheral regions surrounding the CA
and SMA. Our CTV, on the other hand, contained the primary tumor
plus only metastatic regional lymph nodes and peripheral regions
surrounding the CA or SMA in cases of lesions which had invaded
around the vessels. Non-metastatic regional lymph nodes for pro-
phylactic irradiation were not included in our CTV. It may be pos-
sible that differences in the irradiation field caused less severe
adverse events in our study. In parts other than treatment plan-
ning, routine use of proton-pump inhibitors and fasting before
treatment might help to alleviate severe adverse events.
Unresectable LAPC is well-known to undergo distant metas-
tases and the role of radiotherapy as local therapy within the con-
Fig. 2. Survival curves classified to irradiation dose. (a, c) Overall survival rate. (b, d) Local control rate. (a, b): Straight line: 50 GyE. Dotted line: > 50 GyE. (c, d): Straight line:
50 GyE. Dotted line: 54–60 GyE. Broken line: 67.5 GyE (concomitant boost).
Fig. 3. Case presentation. 71-year old man with pancreatic cancer. (a) CT before treatment. Arrows indicate gross tumor volume. (b) Dose distribution image. Total irradiation
dose is 67.5 GyE and isodose lines represent 95–10% of the isocenter dose from inside to outside. (c) CT 25 months after CCRT using proton beams. Arrows indicate a reduced
tumor.
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field size has been reduced according to chemotherapeutic inten-
sity but controversy remains as to how much local lesion controlcould affect outcome of those LAPC patients in which distant
metastases are frequent and lethal [10,41]. However, OS was clo-
sely related with LC in our study and those patients without local
42 PBT for unresectable LAPCrecurrence trended toward longer survival than patients with local
recurrences as shown in Supplementary Fig. 2. Moreover, several
studies dealing with unresectable LAPC patients report that high
dose irradiation improves LC and OS [25,27,31,32]. Taken together,
we can therefore consider that excellent control of the primary
lesions due to high irradiation dose delivery can control primary
tumor activity and prolong survival of unresectable LAPC patients.
In our previous simulation study, the mean primary tumor dose
from our 67.5 GyE in 25 fractions protocol (using concomitant
boost technique) was 66.2 GyE in GI tract-separated tumors,
62.1 GyE in tumors adjacent to the GI tract, and 64.1GyE as a whole
[42]. As shown in the detailed dose classification analysis in Fig. 2,
the OS and LC of patients treated with a 67.5 GyE protocol were
much higher than the conventional 50 GyE protocol and equivalent
or higher than with 54–60 GyE, making it a reasonable and con-
vincing result. Furthermore, dose escalation using concomitant
boost technique can improve treatment effectiveness. Considering
that no patient suffered from severe GI tract toxicity, higher dose
delivery using the concomitant boost technique coupled with the
physical characteristics of proton beams has the potential to safely
and effectively replace the conventional protocol. Further studies
into this could clarify the clinical significance of dose escalation
using the concomitant boost technique.
In our study, a total of 23 patients were concurrently treated by
hyperthermia as machine time allowed. Hyperthermia is known to
increase the blood supply to tumors and improve delivery of large
doses of cytotoxic oxygen and drugs [43]. It also acts as a radiation-
and chemo-sensitizer while inhibiting transcription factors like
NF-kB that play a crucial role in pancreatic carcinoma development
and progression [43–45]. As pancreatic cancer features chemo-
radio resistance and hypoxia, these patients are presumably good
candidates for hyperthermic therapy. Although Maebayashi et al.
[46] previously reported that CCRT combined with hyperthermia
prolonged OS, hyperthermia did not function as a significant prog-
nostic factor for OS and LC in our study. Future optimization stud-
ies are necessary to prove the efficacy of hyperthermic therapy in
proton beam CCRT.
There are several limitations of this study. First, because this is a
retrospective study, our patient populationmight have been biased
toward favoring the effectiveness of PBT for survival or improve-
ment of quality of life. However, the selection of PBT or photon
therapy was arbitrarily done by the patients or referring physicians
without prompting on our part. Additionally, to further reduce any
bias, we performed univariate analyses using several factors. Sec-
ond, variations of chemotherapy regimens, use of hyperthermia
and our irradiation dose protocol might have introduced bias as
an especially wide variety of pre-treatment chemotherapy regi-
mens complicated determination of relevance to outcome. Even
if we had no say in the pre-treatment chemotherapy and did not
base our protocols on patient performance or clinical staging, some
bias inevitably remained. Finally, because of the potentially rapid
progression of disease, some patients could not be regularly exam-
ined at our institute. We made every effort to get as much data as
possible through mail to these patients and physicians but patients
who were shifted to palliative care or died soon after treatment
would complicate any data gathering with regard to exact local
treatment effect.
Clinical reports of PBT for unresectable LAPC patients are extre-
mely scarce but clinical outcomes are satisfactory among CCRT
reports to this point. To the best of our knowledge, this is the first
study to prove the effectiveness of CCRT using proton beams by
clarifying that high dose administration to tumors leads to
improved prognosis for unresectable LAPC patients. We therefore
consider that the physical advantages of proton beams can increase
the value of radiotherapy in local CCRT treatment strategies for
these patients.In conclusion, CCRT using proton beams resulted in longer sur-
vival than previously reported CCRT data using photon RT, and
high dose irradiation to the primary tumor prolonged LC and OS
for unresectable LAPC patients without any severe GI toxicity.
PBT is therefore a safe and effective treatment method for these
patients.Conflict of interest
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